🚀 VC round data is live in beta, check it out!
Daan Gene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Daan Gene and similar public comparables like Guangzhou Wondfo Biotech, Azenta, Sinocare, Ramsay Santé and more.
Daan Gene Overview
About Daan Gene
Daan Gene Co Ltd is a high-tech enterprise-oriented in molecular diagnostic techniques. It is primarily committed to research and development, production, and service of in-vitro diagnostic products, including qPCR, Sequeacing, TRF, ELISA, and Liquid-Based Cytology diagnostic kits and equipment. Geographically, tahe group operates in China.
Founded
1988
HQ
Employees
512
Website
Financials (FY)
EV
$1B
Daan Gene Financials
Daan Gene reported last fiscal year revenue of $125M and negative EBITDA of ($104M).
In the same fiscal year, Daan Gene generated $47M in gross profit, ($104M) in EBITDA losses, and had net loss of ($136M).
Daan Gene P&L
In the most recent fiscal year, Daan Gene reported revenue of $125M and EBITDA of ($104M).
Daan Gene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $125M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $47M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 38% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($104M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (83%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (27%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($136M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (108%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Daan Gene Stock Performance
Daan Gene has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Daan Gene's stock price is $0.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.1% | XXX | XXX | XXX | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaan Gene Valuation Multiples
Daan Gene trades at 8.8x EV/Revenue multiple, and (10.6x) EV/EBITDA.
Daan Gene Financial Valuation Multiples
As of April 18, 2026, Daan Gene has market cap of $1B and EV of $1B.
Equity research analysts estimate Daan Gene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Daan Gene has a P/E ratio of (9.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (32.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 23.5x | XXX | XXX | XXX |
| P/E | — | XXX | (9.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 59.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Daan Gene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Daan Gene Margins & Growth Rates
Daan Gene's revenue in the last fiscal year declined by (28%).
Daan Gene's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Daan Gene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (28%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (83%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (248%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Daan Gene Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Daan Gene | XXX | XXX | XXX | XXX | XXX | XXX |
| Guangzhou Wondfo Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Azenta | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocare | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Santé | XXX | XXX | XXX | XXX | XXX | XXX |
| NeoGenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daan Gene M&A Activity
Daan Gene acquired XXX companies to date.
Last acquisition by Daan Gene was on XXXXXXXX, XXXXX. Daan Gene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Daan Gene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDaan Gene Investment Activity
Daan Gene invested in XXX companies to date.
Daan Gene made its latest investment on XXXXXXXX, XXXXX. Daan Gene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Daan Gene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Daan Gene
| When was Daan Gene founded? | Daan Gene was founded in 1988. |
| Where is Daan Gene headquartered? | Daan Gene is headquartered in China. |
| How many employees does Daan Gene have? | As of today, Daan Gene has over 512 employees. |
| Is Daan Gene publicly listed? | Yes, Daan Gene is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Daan Gene? | Daan Gene trades under 002030 ticker. |
| When did Daan Gene go public? | Daan Gene went public in 2004. |
| Who are competitors of Daan Gene? | Daan Gene main competitors are Guangzhou Wondfo Biotech, Azenta, Sinocare, Ramsay Santé. |
| What is the current market cap of Daan Gene? | Daan Gene's current market cap is $1B. |
| What is the current revenue of Daan Gene? | Daan Gene's last fiscal year revenue is $125M. |
| What is the current EV/Revenue multiple of Daan Gene? | Current revenue multiple of Daan Gene is 8.8x. |
| Is Daan Gene profitable? | No, Daan Gene is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.